Clarivate™

Market insights summary

Latin America gastrointestinal device market

What's trending?

Increasing uptake of noninvasive alternatives to colonoscopies will favor screening volumes, supporting market growth.

- Noninvasive colorectal cancer (CRC) screening alternatives, like fecal immunochemical test (FIT) and liquid biopsy, avoid the patient discomfort associated with screening colonoscopies.
- As a result, these alternatives are being increasingly adopted, enabling more of the target patient pool to participate in CRC screening.
- This will continue to support adenoma detection rates, driving demand for follow-up diagnostic colonoscopies and supporting colonoscopy volumes throughout the forecast period.

Reprocessing challenges and cross-contamination risks will support a shift toward disposable single-use devices.

- While device reuse and reprocessing offers economical advantages, the endoscopy device space has witnessed multiple device recalls and cases of cross contamination associated with these devices.
- Physicians interviewed noted that a high incidence of inefficient reprocessing has led to greater risks of cross contamination.
- Consequently, although some gastrointestinal (GI) endoscopy device reuse will persist, the practice is expected to gradually diminish in the Latin American countries, supporting the uptake of single-use devices in the region.

Access more insights and data in the report.
Speak to our team to see how we can power your innovation.

2024 Latin America gastrointestinal device market snapshot

$931.6M
Market value

4.6%
CAGR ('19–'34)

Latin American GI device market by product type



GI endoscopic procedures by procedure type, 2024



Note: Latin America coverage includes Argentina, Brazil, Chile, Colombia and Mexico. ERCP = Endoscopic Retrograde Cholangiopancreatography; EGD = Esophagogastroduodenoscopy.

Latin American competitive landscape, 2024



The Latin American GI endoscopic device market is diverse, driven by price pressure and dominated by players with broad portfolios. While overall innovation remains limited, certain competitors have been incorporating novel technology to differentiate their products to gain market share. Early market entry and capital equipment offerings provide key competitive advantages, while indication expansions support continued physician trust and brand loyalty. Consumable device segments, like the biopsy device segment, remain open to low-cost manufacturers owing to the cost-constrained nature of this market.